New biotech from Alex­is Borisy will test Mer­ck KGaA, Blue­print can­cer drug com­bo in bid to ful­fill Gleevec promise

Alex­is Borisy and Ben Aus­pitz want to be in­tel­li­gent with their lat­est biotech, not “stu­pid.”

That’s in the words of Borisy, the re­peat biotech en­tre­pre­neur be­hind the likes of Blue­print Med­i­cines and EQRx. He and busi­ness part­ner Aus­pitz, a long-time in­dus­try in­vestor at F-Prime Cap­i­tal, want to bring to­geth­er “in­tel­li­gent­ly de­signed” can­cer drugs, hence their start­up’s name: IDRx.

In launch­ing their lat­est biotech, with a $122 mil­lion Se­ries A, the duo be­lieves it’s brought to­geth­er two drugs that can be “best in class” as a com­bi­na­tion ther­a­py for cer­tain can­cers. At the heart of their new com­pa­ny is an old ven­ture: Blue­print. IDRx has se­cured the li­cense to a Blue­print as­set and a Mer­ck KGaA as­set, with both com­pa­nies re­tain­ing eq­ui­ty stakes in the start­up in ex­change for the trans­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER